...
首页> 外文期刊>Molecular and Cellular Biochemistry >ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria
【24h】

ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria

机译:伊朗II型糖尿病合并白蛋白尿患者的ACE基因多态性和血清ACE活性

获取原文
获取原文并翻译 | 示例

摘要

There are controversial results related to the contribution of insertion (I)/deletion (D) polymorphism of the angiotensin I-converting enzyme (ACE) in the development of diabetic nephropathy. To assess the distribution of this polymorphism in diabetic patients with and without nephropathy we studied 140 unrelated type 2 diabetic patients from the Kermanshah Province of Iran with ethnic background of Kurds including 68 patients with macroalbuminuria and 72 normoalbuinuric diabetic patients as controls. Genotyping was done by polymerase chain reaction (PCR). The frequency of D allele in nephropathic and normoalbuminuric patients were 69.1 and 58.3%, respectively (P = 0.061). In individuals with DD genotype the risk of macroalbuminuria increased 2.87-fold (P = 0.057). Significant lower level of serum ACE activity was found in the normoalbuminuric (59.76 IU/l) compared to macroalbuminuric (97.43 IU/l) patients. The serum ACE activity was significantly higher in macroalbuminuric patients with ID (105.7 IU/l) and ID + DD (100.7 IU/l) genotypes compared to normoalbuminuric patients with the same genotypes (63.5 and 64.2 IU/l, respectively). Treatment with captopril significantly (P = 0.045) reduced the serum ACE activity in normoalbuminuric patients with DD genotype compared to macroalbuminuric patients with the same genotype (33.6 vs. 73.8 IU/l). However, the greatest benefit effect of losartan therapy on ACE activity was observed only in macroalbuminuric patients with DD genotype compared to that in normoalbuminuric patients (61.0 vs. 109.0 IU/l, P = 0.06). Our study suggests the importance of ethnic origin in the development of diabetic nephropathy and demonstrates different responses to therapy according to genotype and stage of diabetes.
机译:有争议的结果涉及糖尿病肾病发展过程中血管紧张素I转换酶(ACE)的插入(I)/缺失(D)多态性的贡献。为了评估这种多态性在有或没有肾病的糖尿病患者中的分布,我们研究了来自伊朗克曼沙赫省,具有库尔德族裔背景的140名无关的2型糖尿病患者,其中包括68名患有大白蛋白尿的患者和72名正常白蛋白尿的糖尿病患者作为对照。基因分型通过聚合酶链反应(PCR)完成。肾病和正常白蛋白尿患者的D等位基因频率分别为69.1%和58.3%(P = 0.061)。在具有DD基因型的个体中,巨蛋白尿的风险增加了2.87倍(P = 0.057)。与正常白蛋白尿(97.43 IU / l)的患者相比,正常白蛋白尿(59.76 IU / l)的血清ACE活性显着降低。 ID(105.7 IU / l)和ID + DD(100.7 IU / l)基因型的大白蛋白尿患者的血清ACE活性显着高于相同基因型(63.5和64.2 IU / l)的正常白蛋白尿患者。与具有相同基因型的大白蛋白尿患者相比,卡托普利治疗显着(P = 0.045)降低了具有DD基因型的白蛋白尿患者的血清ACE活性(33.6 vs. 73.8 IU / l)。然而,与正常白蛋白尿患者相比,氯沙坦疗法对具有DD基因型的大型白蛋白尿患者仅观察到ACE活性的最大获益(61.0 vs. 109.0 IU / l,P = 0.06)。我们的研究表明种族起源在糖尿病性肾病发展中的重要性,并根据糖尿病的基因型和分期显示出对治疗的不同反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号